{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-007467","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.318612+00:00","generated_at":"2026-06-04T23:37:10.839581+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCardia fails to regain Nasdaq compliance; delisting hearings requested","bullets":["Nasdaq determined BioCardia failed to meet $35M MVLS requirement by March 4, 2024.","Also failed to meet minimum bid price of $1.00 by March 11, 2024.","Company requested hearing by March 13, 2024, which stays suspension pending panel decision.","No assurance of continued listing; delisting could impair capital raising and stock liquidity."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-007467","json":"https://secwatch.observer/filing/0001437749-24-007467.json","markdown":"https://secwatch.observer/filing/0001437749-24-007467.md","text":"https://secwatch.observer/filing/0001437749-24-007467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774924007467/0001437749-24-007467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774924007467/bcda20240312c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:37:10.839581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37825c70a02059cf2665ebf247b20f4cf7158c34","claim":"BioCardia, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance with","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774924007467/0001437749-24-007467-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"cdb8265da293e35be79e77abc0b82df3a084f155","claim":"BioCardia, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"March 12, 2024. Additionally, as previously disclosed on a Current Report on Form 8-K filed with the SEC on September 15, 2023, on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774924007467/0001437749-24-007467-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"hearing update"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"d44f5f9e267f62d79a748ec3f395ad3c8eca8298","claim":"BioCardia, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance w","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774924007467/0001437749-24-007467-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}